Roche continues to invest in the future of research in Basel
Roche has laid the foundation stone for the new research and development building, Building 12, at its headquarters in Basel. With an investment of 500 million Swiss francs, the company is strengthening its Swiss research capacities and accelerating drug development.
Building 12 will be completed by 2029 and will provide space for around 450 researchers. It will act as a link between early research and clinical development, enabling new active ingredients to be applied more efficiently. The flexible space concept and state-of-the-art laboratory infrastructure promote interdisciplinary collaboration and technological innovation.
A commitment to Switzerland
Roche has already invested around eight billion Swiss francs in the expansion of its Swiss sites since 2015. Building 12 will extend the Basel innovation axis and further consolidate Switzerland’s position as a leading research location within the Group. According to site manager Jürg Erismann, the building is a “clear commitment to Basel and to Swiss research expertise”.
Architecture and dimensions
The 72-metre-high Building 12, designed by Herzog & de Meuron, will unite previously dispersed research areas under one roof. Laboratories and open work zones for a new generation of drug development will be created on 32,200 square meters. Completion is planned for the end of 2029.
Strategic importance
With the combination of science, technology and architecture, Roche is focusing on accelerating development processes and sustainably strengthening the site. Of the more than 40 billion Swiss francs invested across the Group in the last ten years, around a quarter has been invested in Switzerland. A clear signal of the continued innovative strength of the Basel campus.